The growth hormone with high biological activity modified by the double-stranded polyethylene glycol at a single site and the preparation method thereof are provided. The PEGylated growth hormone has a higher biological activity and a longer half-life than the unmodified growth hormone. The composition comprising the PEGylated growth hormone is useful in the treatment of the growth or development disorder such as growth hormone deficiency, Turner syndrome etc.

The growth hormone with high biological activity modified by the double-stranded polyethylene glycol at a single site and the preparation method thereof are provided. The PEGylated growth hormone has a higher biological activity and a longer half-life than the unmodified growth hormone. The composition comprising the PEGylated growth hormone is useful in the treatment of the growth or development disorder such as growth hormone deficiency, Turner syndrome etc.

The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.

The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.

The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.

The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.

Transgenic microalgae expressing at least one exogenous biologically active protein. The protein-expressing microalgae are used for the oral delivery of the biologically active protein to the target organism in its intact and functional form. The exogenous protein, expressed in algae, is characterized by being biologically active, exerting at least one specific activity having a beneficial effect on the subject consuming the algae. The transgenic microalgae are used as animal food for aquatic or land animals welfare or as food supplement for human healthcare.

Transgenic microalgae expressing at least one exogenous biologically active protein. The protein-expressing microalgae are used for the oral delivery of the biologically active protein to the target organism in its intact and functional form. The exogenous protein, expressed in algae, is characterized by being biologically active, exerting at least one specific activity having a beneficial effect on the subject consuming the algae. The transgenic microalgae are used as animal food for aquatic or land animals welfare or as food supplement for human healthcare.

The present invention relates to dosage units of oral films for the administration of active pharmaceutical ingredients (API), such as analgesics, relaxants, anxiolytics, sedatives, hypnotics, narcotics, anesthetics and/or other API with peripheral and/or central nervous effects, in particular for use in the treatment of pain, metabolic disorders and diseases of the central nervous system (CNS). More particular the invention relates to dosage units of oral films comprising relaxants, anxiolytics, sedatives, hypnotics, narcotics, anesthetics and/or analgesics prone to misuse and abuse, such as overdosing. More particular, the invention relates to dosage units of oral films comprising propofol. In a further aspect, the invention relates to dosage units of oral films comprising propofol for use in the treatment of a subject suffering from migraine.

The present disclosure generally provides complexes including a pharmaceutically active agent and a functionalized polymer, wherein the functionalized polymer includes repeat units, the repeat units including ionizable repeat units having at least one ionizable side group and/or ionizable end group, a plurality of the at least one ionizable groups forming non-covalent bonds with the pharmaceutically active agent. Polymers which may be used to form such complexes as well as methods of making and using the complexes and related compositions are also provided.